101 related articles for article (PubMed ID: 22694172)
1. Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country.
Lucero MC; Diaz-Brito V; Murillo BT; Carretero SC; Sala M; Casadesús C; Conde MS; Jimenez JL; Pich J; Arnaiz JA; Leon A; Perez I; Muñoz-Fernández MÁ; Gatell JM; Plana M; Esteban M; Bernaldo de Quiros JC; Garcia F;
AIDS Patient Care STDS; 2012 Jul; 26(7):379-82. PubMed ID: 22694172
[No Abstract] [Full Text] [Related]
2. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania.
Tarimo EA; Thorson A; Kohi TW; Bakari M; Mhalu F; Kulane A
PLoS One; 2011 Feb; 6(2):e14619. PubMed ID: 21358826
[TBL] [Abstract][Full Text] [Related]
3. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
Chesney MA; Lurie P; Coates TJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
[No Abstract] [Full Text] [Related]
4. HIV vaccines: the Uganda experience.
Mugyenyi PN
Vaccine; 2002 May; 20(15):1905-8. PubMed ID: 11983242
[TBL] [Abstract][Full Text] [Related]
5. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa.
Mamotte N; Wassenaar D; Koen J; Essack Z
BMC Med Ethics; 2010 Mar; 11():3. PubMed ID: 20211030
[TBL] [Abstract][Full Text] [Related]
6. Lack of volunteers for vaccine.
AIDS Patient Care STDS; 1999 Sep; 13(9):572. PubMed ID: 10813047
[No Abstract] [Full Text] [Related]
7. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
Temoshok LR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
[No Abstract] [Full Text] [Related]
8. Social and behavioral issues in phase III HIV preventive vaccine trials.
Grinstead OA
AIDS; 1995; 9 Suppl A():S245-50. PubMed ID: 8819592
[No Abstract] [Full Text] [Related]
9. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.
MacQueen KM; Buchbinder S; Douglas JM; Judson FN; McKirnan DJ; Bartholow B
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314
[No Abstract] [Full Text] [Related]
10. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial.
Harrison K; Vlahov D; Jones K; Charron K; Clements ML
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):386-90. PubMed ID: 7552502
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials.
Fureman I; Meyers K; McLellan AT; Metzger D; Woody G
AIDS Educ Prev; 1997 Aug; 9(4):330-41. PubMed ID: 9376207
[TBL] [Abstract][Full Text] [Related]
12. First Spanish HIV vaccine proves safe in phase I trials.
Iriberri A
BMJ; 2011 Oct; 343():d6327. PubMed ID: 21968183
[No Abstract] [Full Text] [Related]
13. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge.
Mills E; Nixon S; Singh S; Dolma S; Nayyar A; Kapoor S
PLoS Med; 2006 Mar; 3(3):e94. PubMed ID: 16478295
[TBL] [Abstract][Full Text] [Related]
14. First AIDS vaccine trial begins in Africa.
AIDS Patient Care STDS; 1999 May; 13(5):309-10. PubMed ID: 10356817
[No Abstract] [Full Text] [Related]
15. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand.
Thapinta D; Jenkins RA; Morgan PA; Chiu J; Boenim W; Bussaratid V; Chaddic C; Naksrisook S; Phonrat B; Sirijongdee N; Sornsathapornkul P; Sontirat A; Srisaengchai P; Suwanarach C; Wongkamhaeng S; Brown AE; Khamboonruang C; Nitayaphan S; Pitisuttithum P; Thongchareon P;
J Acquir Immune Defic Syndr; 2002 Aug; 30(5):503-13. PubMed ID: 12154341
[TBL] [Abstract][Full Text] [Related]
16. HIV vaccine reduces infection rate by a third, study shows.
Mayor S
BMJ; 2009 Sep; 339():b3963. PubMed ID: 19783576
[No Abstract] [Full Text] [Related]
17. First-in-human HIV-remission studies: reducing and justifying risk.
Dresser R
J Med Ethics; 2017 Feb; 43(2):78-81. PubMed ID: 27143494
[TBL] [Abstract][Full Text] [Related]
18. (Un)risky business: adolescents and HIV prevention trials.
Philpott S
Am J Bioeth; 2011 Jun; 11(6):17-9. PubMed ID: 21678207
[No Abstract] [Full Text] [Related]
19. Ethical issues in HIV vaccine trials in South Africa.
Slack C; Lindegger G; Vardas E; Richter L; Strode A; Wassenaar D
S Afr J Sci; 2000 Jun; 96():291-5. PubMed ID: 11863014
[TBL] [Abstract][Full Text] [Related]
20. Scientific justification for the participation of children and adolescents in HIV-1 vaccine trials in South Africa.
Jaspan HB; Gray GE; Robinson AK; Coovadia HM; Bekker LG
S Afr Med J; 2005 Sep; 95(9):685-7. PubMed ID: 16327928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
